5 Things To Know About The FDA's Shift From Animal Testing

A pivotal shift is underway in drug development as the industry moves beyond traditional animal testing toward more predictive, human-relevant methods. This transition, marked by recent regulatory changes, signals not only a modernization of testing practices but also an opportunity to improve the efficiency, accuracy, and ethics of therapeutic evaluation.

At the forefront of this evolution is Abzena, combining advanced computational platforms with sophisticated laboratory models to help developers make smarter, earlier decisions about candidate safety, efficacy, and manufacturability. With tools designed to reflect real human biology and anticipate complex biological responses, these innovations are shaping a new standard for early-stage drug development. In a field where time, precision, and confidence are everything, integrating next-generation approaches is no longer optional—it’s essential.

What follows is a closer look at how these technologies are redefining the pathway from discovery to clinic, and why staying ahead of the curve has never been more important.